You are here: Industry Insights > pneumonia

News List

A Summary and Interpretation of the Progress of Clinical Trials Relating to the Novel Coronavirus Pneumonia (1) PharmaSources/zhulikou431
February 14, 2020
The novel coronavirus pneumonia incident that started to occur in Wuhan City, Hubei Province from Dec. 2019 has produced continuous impacts on the Chinese people.
Internally-developed vaccines reportedly approved in China europeanpharmaceuticalreview
January 09, 2020
According to a recent article, China has approved a number of home-grown vaccines, offering alternatives to global drugmakers’ products.
AR-105 for Ventilator-Associated Pneumonia Does Not Meet Primary Endpoint americanpharmaceuticalreview
September 04, 2019
Aridis Pharmaceuticals announced results from the Company's first-in-patient Phase 2 clinical trial evaluating AR-105, a fully human IgG1 monoclonal antibody for the treatment of ventilator-associated pneumonia ...
FDA Approves Antibiotic for Community-Acquired Pneumonia contractpharma
August 22, 2019
Patients treated with Xenleta had similar rates of clinical success as those treated with moxifloxacin with or without linezolid.
New Antibiotic Xenleta Approved for Community-Acquired Bacterial Pneumonia drugs
August 20, 2019
Xenleta (lefamulin) has been approved to treat adults with community-acquired bacterial pneumonia, the U.S. Food and Drug Administration announced .
Poor Pneumonia Outcomes Tied to Overuse of Broad-Spectrum Antibiotics drugs
August 07, 2019
Overuse of broad-spectrum antibiotics is associated with increased mortality and other poor outcomes in adults admitted for community-onset pneumonia...
Many Pneumonia Patients Get Too Many Antibiotics drugs
July 15, 2019
Two-thirds of hospitalized pneumonia patients may be prescribed antibiotics for too long, increasing their risk for potentially harmful side effects, researchers say.
Hospitalized Pneumonia Patients Often Get Excess Antibiotics drugs
July 12, 2019
Patients hospitalized with pneumonia often receive excess antibiotic therapy, according to a study published online in the Annals of Internal Medicine.
FDA Approves Treatment for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia americanpharmaceuticalreview
June 06, 2019
The U.S. Food and Drug Administration (FDA) approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP
Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia drugs
June 05, 2019
Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia.

Previous page 1 2 3 4 5 Next page